Literature DB >> 30659131

Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Wui-Jin Koh, Nadeem R Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M Campos, Kathleen R Cho, Hye Sook Chon, Christina Chu, Rachel Clark, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J Eifel, Christine M Fisher, Peter Frederick, David K Gaffney, Ernest Han, Warner K Huh, John R Lurain, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W Remmenga, R Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M Yashar, Nicole R McMillian, Jillian L Scavone.   

Abstract

Cervical cancer is a malignant epithelial tumor that forms in the uterine cervix. Most cases of cervical cancer are preventable through human papilloma virus (HPV) vaccination, routine screening, and treatment of precancerous lesions. However, due to inadequate screening protocols in many regions of the world, cervical cancer remains the fourth-most common cancer in women globally. The complete NCCN Guidelines for Cervical Cancer provide recommendations for the diagnosis, evaluation, and treatment of cervical cancer. This manuscript discusses guiding principles for the workup, staging, and treatment of early stage and locally advanced cervical cancer, as well as evidence for these recommendations. For recommendations regarding treatment of recurrent or metastatic disease, please see the full guidelines on NCCN.org.
Copyright © 2019 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2019        PMID: 30659131     DOI: 10.6004/jnccn.2019.0001

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   12.693


  204 in total

1.  Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018.

Authors:  Lucia Manganaro; Yulia Lakhman; Nishat Bharwani; Benedetta Gui; Silvia Gigli; Valeria Vinci; Stefania Rizzo; Aki Kido; Teresa Margarida Cunha; Evis Sala; Andrea Rockall; Rosemarie Forstner; Stephanie Nougaret
Journal:  Eur Radiol       Date:  2021-04-14       Impact factor: 5.315

2.  Minimally Invasive Radical Hysterectomy for Cervical Cancer: When Adoption of a Novel Treatment Precedes Prospective, Randomized Evidence.

Authors:  Alexander Melamed; J Alejandro Rauh-Hain; Pedro T Ramirez
Journal:  J Clin Oncol       Date:  2019-09-27       Impact factor: 44.544

3.  Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes.

Authors:  Benny Brandt; Vasileios Sioulas; Derman Basaran; Theresa Kuhn; Katherine LaVigne; Ginger J Gardner; Yukio Sonoda; Dennis S Chi; Kara C Long Roche; Jennifer J Mueller; Elizabeth L Jewell; Vance A Broach; Oliver Zivanovic; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2020-01-07       Impact factor: 5.482

4.  Survey of the clinical practice pattern of using sentinel lymph node biopsy in patients with gynecological cancers in Japan: the Japan Society of Gynecologic Oncology study.

Authors:  Shinichi Togami; Hiroaki Kobayashi; Hitoshi Niikura; Muneaki Shimada; Nobuyuki Susumu; Tomohito Tanaka; Yoshito Terai; Tomoyuki Nagai; Tsukasa Baba; Hideaki Yahata; Wataru Yamagami; Ken Yamaguchi; Tsuyoshi Yamashita; Nobuo Yaegashi; Hidetaka Katabuchi; Daisuke Aoki
Journal:  Int J Clin Oncol       Date:  2021-03-25       Impact factor: 3.402

5.  PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.

Authors:  Anna Bianchi; Salvatore Lopez; Gary Altwerger; Stefania Bellone; Elena Bonazzoli; Luca Zammataro; Aranzazu Manzano; Paola Manara; Emanuele Perrone; Burak Zeybek; Chanhee Han; Gulden Menderes; Elena Ratner; Dan-Arin Silasi; Gloria S Huang; Masoud Azodi; Justin Y Newberg; Dean C Pavlick; Julia Elvin; Garrett M Frampton; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2019-08-18       Impact factor: 5.482

6.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

Authors:  Robert L Coleman; Gini F Fleming; Mark F Brady; Elizabeth M Swisher; Karina D Steffensen; Michael Friedlander; Aikou Okamoto; Kathleen N Moore; Noa Efrat Ben-Baruch; Theresa L Werner; Noelle G Cloven; Ana Oaknin; Paul A DiSilvestro; Mark A Morgan; Joo-Hyun Nam; Charles A Leath; Shibani Nicum; Andrea R Hagemann; Ramey D Littell; David Cella; Sally Baron-Hay; Jesus Garcia-Donas; Mika Mizuno; Katherine Bell-McGuinn; Danielle M Sullivan; Bruce A Bach; Sudipta Bhattacharya; Christine K Ratajczak; Peter J Ansell; Minh H Dinh; Carol Aghajanian; Michael A Bookman
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

7.  ENO1 monoclonal antibody inhibits invasion, proliferation and clone formation of cervical cancer cells.

Authors:  Yuanfeng Gou; Fei Li; Xiaqin Huo; Chunyan Hao; Xiaojuan Yang; Yaping Pei; Na Li; Huiling Liu; Bingdong Zhu
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

8.  Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial.

Authors:  Andreas Obermair; Rebecca Asher; Rene Pareja; Michael Frumovitz; Aldo Lopez; Renato Moretti-Marques; Gabriel Rendon; Reitan Ribeiro; Audrey Tsunoda; Vanessa Behan; Alessandro Buda; Marcus Q Bernadini; Hongqin Zhao; Marcelo Vieira; Joan Walker; Nick M Spirtos; Shuzhong Yao; Naven Chetty; Tao Zhu; David Isla; Mariano Tamura; James Nicklin; Kristy P Robledo; Val Gebski; Robert L Coleman; Gloria Salvo; Pedro T Ramirez
Journal:  Am J Obstet Gynecol       Date:  2019-10-03       Impact factor: 8.661

9.  Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.

Authors:  Michael Frumovitz; Shannon N Westin; Gloria Salvo; Abdulrazzak Zarifa; Mingxuan Xu; Timothy A Yap; Ahnert J Rodon; Daniel D Karp; Abdulrahman Abonofal; Amir A Jazaeri; Aung Naing
Journal:  Gynecol Oncol       Date:  2020-06-11       Impact factor: 5.482

10.  Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy.

Authors:  Sharad Purohit; Daron G Ferris; Manual Alvarez; Paul M H Tran; Lynn K H Tran; David P Mysona; Diane Hopkins; Wenbo Zhi; Boying Dun; John J Wallbillich; Richard D Cummings; Peng George Wang; Jin-Xiong She
Journal:  Gynecol Oncol       Date:  2020-01-17       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.